US · Healthcare · Biotechnology
EPS came in at -0.35 against a street estimate of -0.43 — a beat of 18.6%.
Analysts rate Acumen Pharmaceuticals Inc a strong buy (6 buy, 0 hold, 0 sell out of 6) with an average price target of $7.60.
CAUTIOUS Acumen expects ALTITUDE-AD Phase II results in November. Management sees potential for meaningful efficacy and differentiated safety, but the company remains loss-making with cash funding operations into early 2027. Q3 FY26 No geographic or regional performance was discussed. Analysts focused on ALTITUDE-AD success criteria, dose differences, retention, follow-on use and EBD development. Management emphasized the November readout, potential efficacy at both doses and continued program optionality. 2026-10-26…
Full summary in the app.
| Fund | Stake |
|---|---|
| RA Capital Management, LLC | 29.03% |
| Sands Capital Ventures, LLC | 5.14% |
| BlackRock Inc | 3.44% |
| Alyeska Investment Group, L.P. | 3.39% |
| Franklin Templeton Inc | 3.19% |
| ADAR1 Capital Management LLC | 2.92% |
| Vanguard Capital Management, LLC | 2.31% |
| Knollwood Investment Advisory LLC | 2.25% |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Acumen Pharmaceuticals Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.